

11 April 2023

ASX ANNOUNCEMENT

US PENTHROX STRATEGY

Medical Developments International (ASX: MVP) today formally approved the strategic pathway for commercialising Pentrox in the US. The Company will now commence a search for partner organisations to undertake the clinical and non-clinical programs and to launch Pentrox in this market.

CEO, Brent MacGregor said, *"We are in the final stages of a comprehensive commercial assessment of the US. Feedback received through this review affirms the substantial opportunity for Pentrox in this market, which is the world's largest for pharmaceuticals. It is clear that delivering value from Pentrox in the US will be best achieved through the support of one or more partners."*

The Company will provide further progress updates on the US Pentrox strategy in the coming months.

~END~

Authorised for release by the Board of Directors.

Enquiries:

Tara Eaton
Company Secretary
+61 (3) 9547 1888

Anita James
Chief Financial Officer
+61 (3) 9547 1888

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications.